Senate committee passes bill squeezing PBMs, attacking anticompetitive drug company practices

The Lower Health Care Costs Act (S. 1895), a bipartisan drug pricing bill, took a big step toward enactment Wednesday as the Health, Education, Labor and Pensions Committee passed it in a 17-3 vote. The bill is likely to be passed by the Senate, and could be endorsed by the House.

The HELP Committee voted to add a bill making companies justify price increases with extensive disclosures about development and marketing costs (see “HELP Committee Advances Transparency Bill”).

S. 1895 seeks to squeeze PBM profits out of the drug

Read the full 897 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE